Efeito do docetaxel e da ciclofosfamida nas alterações da matriz óssea

• Autor(a) principal: Andrade, Cherley Borba Vieira de
• Data de Publicação: 2013
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/16153
• topic: Breast câncer; Early menopause; Osteoporosis; Docetaxel; Câncer de mama; Menopausa precoce; Osteoporose; Docetaxel; Mamas - Câncer; Neoplasias da mama - Quimioterapia; Osteoporose; Antineoplásicos - Uso terapêutico; CNPQ::CIENCIAS BIOLOGICAS::BIOFISICA

The World Health Organization (WHO) estimates for 2030, 27 million incident cases of cancer. In Brazil, according to the National Cancer Institute, there were estimated 518,510 new cases of cancer for the years 2012 and 2013. From this estimation, 52,680 will correspond to breast cancer (BC), with an estimated risk of 52 new cases per 100,000 women. BC is one of the most common cancers worldwide. Today it is known that the treatment of the BC may lead to the emergence of different late adverse effects, including osteoporosis. One of the main causes of osteoporosis is the early menopause, which occurs with decreasing the serum estrogen concentration. This study aimed to evaluate the effects on bone matrix induced by chemotherapy , simulating a treatment for BC in Wistar rats .Wistar rats, approximately 3 months old, were divided into a control group and the group receiving polichemotherapy with docetaxel + cyclophosphamide (TC). Chemotherapy was administered in 4 cycles, with an interval of 1 week between them. The rats were euthanized 5 months after the end of treatment, so that the late effects could be evaluated. Several studies were performed: dosage of serum estradiol levels, histological tests by immunohistochemistry, micro X-ray fluorescence, micro-computed tomography and also transmission and scanning electron microscopy.Analyzing the results together, it is suggested that the initial step in the development of osteoporosis caused by multidrug TC is the reduction in the ovarian function. This event leads to decreased serum concentration of estrogen, which causes uterine atrophy. Concomitant to these facts, the TC causes a reduction in the concentration of zinc in the bone tissue. These results associated cause an imbalance in the osteoblast/osteoclast ratio in the bone tissue. The reduction in estrogen leads to decreased apoptosis of osteoclasts, while the reduction of zinc inhibits osteoblast function. This imbalance affects the bone turnover in order to increase bone resorption. Thus, the percentage of bone is reduced, and the trabeculae become thinner and spaced. The endpoint of this process is osteoporosis.The administration of docetaxel and cyclophosphamide together leads to decreased bone mass in the trabecular, thinning and increasing the space between them. These observations suggest that the rats treated with TC developed osteoporosis. We conclude that both the estrogen and the zinc play a fundamental role in the development of this disease after chemotherapy with TC.